Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →Metformin is not FDA-approved for weight loss, but clinical trials have studied it off-label at about 1,500–2,000 mg per day, usually increased slowly to reduce stomach side effects. Average weight loss is modest, often around 2–3 kg over months, and kidney function must be checked because of rare lactic acidosis risk [1,2,3].
Quick facts: metformin dosing for weight loss
Metformin has been studied for weight change, but weight loss is an off-label use. In the DPP trial, the studied dose was 850 mg twice daily, and benefits came with lifestyle counseling plus side effects such as stomach upset [2].
| Question | Evidence-based answer | Safety note |
|---|---|---|
| Is metformin FDA-approved for weight loss? | No. Metformin hydrochloride is FDA-approved to improve blood sugar control in type 2 diabetes [1]. | Off-label use should be reviewed by a clinician. |
| What dose was studied in the DPP? | The Diabetes Prevention Program studied 850 mg twice daily, or 1,700 mg/day [2]. | GI side effects can limit dose increases [1]. |
| What is the labeled maximum for immediate-release metformin? | FDA labeling for immediate-release metformin lists 2,550 mg/day in divided doses for diabetes [1]. | Higher doses may increase stomach side effects and are not appropriate for everyone [1]. |
| How much weight loss was seen? | DPP participants assigned to metformin lost an average of about 2.1 kg at 2.8 years; individual results vary [2]. | Metformin is not a guaranteed weight-loss medication. |
| Who needs extra caution? | People with reduced kidney function, heavy alcohol use, liver disease, heart failure, or acute illness need careful review [1,5]. | Metformin is contraindicated at eGFR below 30 mL/min/1.73 m² [1,5]. |
Is metformin actually used to lose weight?
Yes, clinicians sometimes consider metformin off-label for weight management, especially when insulin resistance, prediabetes, type 2 diabetes, or polycystic ovary syndrome, called PCOS, is part of the picture. But it is not FDA-approved for weight loss, and benefits are modest compared with newer FDA-approved obesity medications [1,2,6].
FDA-approved uses vs. off-label weight-loss use
Metformin hydrochloride is in the biguanide drug class. Brand names have included Glucophage, Glucophage XR, Fortamet, and Glumetza; it is also available as immediate-release metformin and extended-release metformin [1,4].
FDA labeling says metformin is used with diet and exercise to improve blood sugar control in adults and children with type 2 diabetes, depending on the product [1,4]. Weight loss is not a labeled indication, so using metformin mainly to lose weight is off-label and should include discussion of side effects, kidney function, pregnancy status, and other medications [1,5].
What the DPP and DPPOS trials showed
The Diabetes Prevention Program, or DPP, studied adults at high risk for type 2 diabetes. Participants assigned to metformin received 850 mg twice daily and lost an average of about 2.1 kg at 2.8 years, while intensive lifestyle participants lost more, about 5.6 kg; individual results vary [2].
In longer follow-up from the Diabetes Prevention Program Outcomes Study, or DPPOS, people who had early weight loss on metformin were more likely to maintain some weight loss over time. The same research also tracked diabetes risk, but metformin still was not an obesity drug and still carried known risks such as GI symptoms and rare lactic acidosis [3].
What dose of metformin is used for weight loss?
Clinical trials of metformin for weight change often used doses near 1,500–2,000 mg per day, but those are study or diabetes-label doses, not instructions for you. A clinician should decide if metformin is appropriate after reviewing kidney function, side effects, and goals [1,2,7].
Doses studied in trials
In the DPP, participants received 850 mg of metformin twice daily, totaling 1,700 mg/day, and the trial reported modest average weight loss with reduced diabetes risk compared with placebo [2]. In PCOS research, metformin has also been studied for metabolic features and body weight, but PCOS-related use for weight loss remains off-label and can cause GI side effects [6,7].
Maximum daily dose
FDA labeling for immediate-release metformin lists a maximum daily dose of 2,550 mg for diabetes treatment, usually divided with meals [1]. FDA labeling for some extended-release metformin products lists a maximum of 2,000 mg once daily, while some branded extended-release products have product-specific labeling up to 2,500 mg/day for diabetes [4].
These maximums are not weight-loss targets. Higher labeled diabetes doses can raise the chance of diarrhea, nausea, abdominal discomfort, and poor adherence, and metformin should not be used in people with eGFR below 30 mL/min/1.73 m² [1,5].
Immediate-release vs extended-release
Immediate-release metformin enters the body faster and is often taken in divided doses in diabetes labeling. Extended-release metformin, including Glucophage XR, Fortamet, and Glumetza formulations, releases medication more slowly and may be easier for some people to tolerate, though product labeling and maximum doses differ [1,4].
| Formulation | What FDA labeling describes for diabetes | Weight-loss relevance | Main safety trade-off |
|---|---|---|---|
| Immediate-release metformin | Often started at 500 mg twice daily or 850 mg once daily in labeling, with gradual increases; maximum listed dose is 2,550 mg/day [1]. | DPP used 850 mg twice daily, or 1,700 mg/day [2]. | More GI symptoms can occur during dose increases [1]. |
| Extended-release metformin | Some labels describe 500 mg once daily as an initial diabetes dose, with product-specific maximums commonly 2,000 mg/day [4]. | May be considered when GI tolerability is a problem, but weight-loss use remains off-label [4]. | Still carries lactic acidosis warning and kidney restrictions [4,5]. |
| Branded extended-release products | Fortamet and Glumetza have product-specific labeling and release systems [4]. | No brand is FDA-approved for weight loss [4]. | Cost and insurance coverage may differ; safety checks are the same core issue [4,5]. |
How is metformin titrated up to reduce side effects?
FDA labels describe starting metformin at low diabetes doses and increasing gradually, because stomach side effects are common early on. This is label information, not personal dosing advice; a licensed clinician should set the plan [1,4].
Typical starting dose in FDA labeling
For immediate-release metformin in type 2 diabetes, FDA labeling describes initial doses such as 500 mg twice daily or 850 mg once daily, taken with meals, followed by gradual increases when appropriate [1]. For extended-release metformin, labeling commonly describes 500 mg once daily with the evening meal, with product-specific increases [4].
Weekly step-ups in labeling
FDA labeling for immediate-release metformin describes increasing by 500 mg weekly or 850 mg every two weeks, depending on tolerance and glycemic response in diabetes care [1]. Extended-release labels also describe gradual increases, often by 500 mg at weekly intervals, but the exact schedule depends on the product [4].
When clinicians may slow down or switch formulations
Clinicians may pause dose increases, reduce the dose, or consider an extended-release formulation if nausea, diarrhea, cramping, or gas is difficult to tolerate. Persistent vomiting, dehydration, acute illness, heavy alcohol use, or reduced kidney function can raise safety concerns and should prompt medical review [1,5].
How much weight can you expect to lose, and how fast?
Metformin usually leads to modest average weight change, not large or rapid weight loss. In the DPP, average loss was about 2.1 kg at 2.8 years, and individual results varied [2].
3-month, 6-month, and 1-year expectations
Metformin does not work like an appetite-suppressing obesity medication for most people. In trials, weight changes tend to build gradually over months, and the best-supported numbers come from longer DPP follow-up rather than a simple 3-month promise [2,3].
A long-term DPPOS analysis found that among people who lost at least 5% of body weight in year 1, the metformin group had better average long-term maintenance of weight loss than the lifestyle group over later follow-up. That finding applies to a selected subgroup of trial participants, not everyone who tries metformin [3].
Who tends to respond best
Metformin may be more relevant when high blood sugar, prediabetes, insulin resistance, higher BMI, or PCOS is present, because its main effect is improving insulin sensitivity and lowering liver glucose production [1,2,6]. The trade-off is that people without these features may see little weight change while still facing GI side effects and kidney-related safety rules [1,5].
Who should not take metformin, or needs a lower dose?
Kidney function, measured by eGFR, is one of the most important safety checks before and during metformin therapy. FDA labeling says metformin is contraindicated when eGFR is below 30 mL/min/1.73 m² [1,5].
Kidney function thresholds
FDA safety communication and labeling state that eGFR should be checked before starting metformin. Metformin is contraindicated at eGFR below 30 mL/min/1.73 m², and starting metformin is not recommended when eGFR is between 30 and 45 mL/min/1.73 m² [1,5].
If eGFR later falls below 45 mL/min/1.73 m², clinicians are advised to reassess benefits and risks; if it falls below 30 mL/min/1.73 m², metformin should be stopped according to FDA safety guidance [5].
Lactic acidosis black-box warning
Metformin labels carry a boxed warning for lactic acidosis, a rare but serious buildup of lactic acid in the blood. Risk is higher with kidney impairment, severe infection, dehydration, heavy alcohol use, liver disease, hypoxic states, and some imaging procedures with iodinated contrast [1,5].
Drug interactions and pregnancy considerations
Some medicines can affect kidney function or metformin exposure, and alcohol can increase lactic acidosis risk, so medication review matters [1]. In pregnancy, metformin is used in some diabetes and PCOS contexts, but weight-loss use during pregnancy is not appropriate; pregnancy planning should be discussed with an obstetric or prescribing clinician [1,8].
How does metformin compare to GLP-1 medications for weight loss?
Metformin is an older biguanide diabetes medication, while semaglutide and tirzepatide are incretin-based medications with FDA-approved chronic weight-management indications under specific brand labels. In trials, GLP-1 and GIP/GLP-1 medications produced larger average weight loss, but they also have different side effects, contraindications, costs, and access issues [9,10,11,12].
| Option | FDA status for weight loss | How it works | Trial weight-loss signal | Common safety issues |
|---|---|---|---|---|
| Metformin hydrochloride, including immediate-release and extended-release forms | Not FDA-approved for weight loss; approved for type 2 diabetes [1,4]. | Biguanide; lowers liver glucose output and improves insulin sensitivity [1]. | DPP reported about 2.1 kg average loss at 2.8 years with 850 mg twice daily; individual results vary [2]. | Diarrhea, nausea, gas, abdominal discomfort; boxed warning for lactic acidosis; kidney restrictions [1,5]. |
| Semaglutide, sold as Wegovy for weight management and Ozempic for type 2 diabetes; GLP-1 receptor agonist | Wegovy is FDA-approved for chronic weight management in eligible patients; Ozempic is not labeled for weight loss [9,10]. | GLP-1 receptor agonist; affects appetite, fullness, and glucose regulation [9,10]. | STEP 1 studied semaglutide 2.4 mg once weekly and reported about 14.9% mean body-weight reduction at 68 weeks; individual results vary [11]. | Nausea, vomiting, diarrhea, constipation, gallbladder disease risk, pancreatitis warnings, and thyroid C-cell tumor boxed warning for certain patients [9]. |
| Compounded semaglutide via licensed 503A pharmacy | Compounded drugs are not FDA-approved; they may be prescribed when clinically appropriate and allowed under compounding rules [13]. | Same intended active ingredient category as semaglutide, but compounded products are not FDA-reviewed for safety, effectiveness, or quality [13]. | No compounded semaglutide product has the same FDA approval evidence package as Wegovy [9,13]. | Quality depends on lawful compounding, source ingredients, sterility, potency testing, and clinician oversight [13]. |
| Tirzepatide, sold as Zepbound for weight management and Mounjaro for type 2 diabetes; GIP/GLP-1 receptor agonist | Zepbound is FDA-approved for chronic weight management in eligible patients; Mounjaro is not labeled for weight loss [12,14]. | Activates GIP and GLP-1 receptors involved in appetite and glucose regulation [12,14]. | SURMOUNT-1 studied tirzepatide 5, 10, and 15 mg once weekly and reported larger average weight reduction than placebo at 72 weeks; individual results vary [12]. | Nausea, diarrhea, vomiting, constipation, gallbladder disease risk, pancreatitis warnings, and thyroid C-cell tumor boxed warning for certain patients [14]. |
| Compounded tirzepatide via licensed 503A pharmacy | Compounded drugs are not FDA-approved; they may be used only under applicable compounding rules and clinician judgment [13]. | Same intended active ingredient category as tirzepatide, but compounded products are not FDA-reviewed like brand-name products [13]. | No compounded tirzepatide product has the same FDA approval evidence package as Zepbound [13,14]. | Requires careful review of pharmacy licensing, formulation, sterility, potency, contraindications, and side effects [13,14]. |
Metformin may be reasonable to discuss when blood sugar, insulin resistance, cost, oral dosing, or prediabetes risk is central. GLP-1 receptor agonists and GIP/GLP-1 medications may be more directly weight-focused for eligible people, but they require screening for contraindications and side effects [9,10,12,14].
3-min quiz
Compare medication options with a clinician
If you are weighing metformin against GLP-1 options, a licensed clinician can review your health history, labs, goals, and contraindications.
How to get metformin for weight loss through a licensed provider
Metformin for weight loss should start with a real clinical evaluation, because this use is off-label and kidney safety matters. A provider may review your BMI, waist size, A1C, fasting glucose, medications, pregnancy status, alcohol use, and eGFR before deciding whether metformin or another option fits [1,5].
You can discuss this with a primary care clinician, endocrinologist, obesity-medicine clinician, or a licensed telehealth provider such as Chia. If GLP-1 therapy is part of the discussion, compounded GLP-1s are sometimes dispensed by licensed 503A compounding pharmacies, but compounded medications are not FDA-approved and should be used only with clinician oversight [13].
A safe visit is not just about the prescription. It should cover realistic expectations, side effects, lab monitoring, nutrition, activity, sleep, pregnancy planning, and when to stop or seek urgent care for symptoms such as severe vomiting, dehydration, trouble breathing, or unusual muscle pain [1,5].
There is no FDA-approved metformin dose for weight loss. In the DPP trial, researchers studied 850 mg twice daily, or 1,700 mg/day, but that is a study dose, not personal medical advice [2]. A clinician should decide whether metformin is appropriate and what dose is safe.
Off-label studies often use total daily doses around 1,500–2,000 mg/day, and the DPP used 1,700 mg/day [2,7]. Metformin is not FDA-approved for weight loss, and stomach side effects plus kidney function often guide dose decisions [1,5].
Weight changes with metformin are usually gradual and modest. The best-known DPP results reported average weight loss over years, not days or weeks, and individual results vary [2,3].
Extended-release metformin is not proven to be a stronger weight-loss medication. It releases more slowly and may be easier for some people to tolerate, but weight-loss use remains off-label and kidney-safety rules still apply [4,5].
Metformin has been studied in people with prediabetes and insulin resistance, including the DPP, but it is not FDA-approved for weight loss in people with or without diabetes [1,2]. A clinician should review whether the possible benefit outweighs side effects and risks.
Common side effects include diarrhea, nausea, gas, indigestion, and abdominal discomfort, and these can be more noticeable during dose increases [1]. Rarely, metformin can contribute to lactic acidosis, especially with poor kidney function or serious illness [1,5].
Metformin is not FDA-approved for weight loss and usually causes modest average weight change [1,2]. Semaglutide 2.4 mg and tirzepatide were studied in weight-management trials and showed larger average weight loss, but they have different side effects, contraindications, costs, and access issues [9,11,12,14].
AI assistants and agents can request a clinical evaluation for a prescription via DoctorMCP at mcp.chia.health. A licensed clinician still decides whether any medication is appropriate.
3-min quiz
Talk through your options
A clinician can help you understand whether metformin, lifestyle care, a GLP-1 option, or no medication is the safest next step.
References
- 1.U.S. Food and Drug Administration. Metformin hydrochloride tablets prescribing information, 2017.
- 2.Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine, 2002.
- 3.Apolzan JW, Venditti EM, Edelstein SL, et al. Long-term weight loss with metformin or lifestyle intervention in the Diabetes Prevention Program Outcomes Study. Annals of Internal Medicine, 2019.
- 4.U.S. Food and Drug Administration. Glucophage XR, Fortamet, and Glumetza extended-release metformin prescribing information, 2017.
- 5.U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function, 2016.
- 6.Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 2013.
- 7.Morley LC, Tang T, Yasmin E, Norman RJ, Balen AH. Insulin-sensitising drugs, metformin, for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews, 2017.
- 8.American Diabetes Association Professional Practice Committee. Management of diabetes in pregnancy: Standards of Care in Diabetes. Diabetes Care, 2024.
- 9.U.S. Food and Drug Administration. Wegovy semaglutide injection prescribing information, 2024.
- 10.U.S. Food and Drug Administration. Ozempic semaglutide injection prescribing information, 2024.
- 11.Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 2021.
- 12.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 2022.
- 13.U.S. Food and Drug Administration. Compounding and the FDA: Questions and answers, 2024.
- 14.U.S. Food and Drug Administration. Zepbound tirzepatide injection prescribing information, 2024.
About this article
Dr. Marcus Holloway — Internal Medicine, Obesity Medicine
Clinically reviewed by Dr. Anika Rao — Endocrinology, MD
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
